Prihlásiť sa Zaregistrujte sa zadarmo

Budúce P/E spoločnosti 180 Life Sciences

Aká je hodnota metriky Budúce P/E spoločnosti 180 Life Sciences?

Hodnota metriky Budúce P/E spoločnosti 180 Life Sciences Corp. je 6.08

Aká je definícia metriky Budúce P/E?



Budúci pomer P/E (Forward price to earnings ratio) vyjadruje pomer súčasnej ceny a odhadovaného zisku na akciu za ďalších 12 mesiacov.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Budúce P/E spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou 180 Life Sciences

Čomu sa venuje spoločnosť 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Firmy s metrikou budúce p/e podobnou spoločnosti 180 Life Sciences